RE: Good time to buy in here?25 Sep 2018 12:45
Hi Sister8,
I have provided some key figures from the interim account posted August 2018 and they infer a very good year ending 31.12.2018, HIK sit in my portfolio for some time and I have no reason to sell. as you say a stable pharma. I was glad to see the level of debt was reduced. IMO that could be an issue.
ATB
DAR
Group revenue of $989 million, up 11% and in constant currency up 10%1
· Operating profit of $174 million, up 54%
· Core2 Group operating profit of $214 million, up 22% and up 23% in constant currency
· Core basic earnings per share of 61.4 cents, up 35% and up 38% in constant currency
· Basic earnings per share of 44.0 cents, up 53% and up 57% in constant currency
· Cashflow from operations of $185 million
· Net debt reduced to $501 million (31 Dec 2017: $546 million) and healthy leverage ratios maintained
· Interim dividend of 12 cents per share, up from 11 cents per share
· Guidance raised for Injectables and Generics businesses and reiterated for Branded business